| abstract |
The present invention aims to identify an effective method for treating solid cancers and to provide a pharmaceutical for this purpose. The present invention relates to a therapeutic agent against solid cancers, which contains N- {5 - [(6,7-dimethoxy-4-quinolinyl) oxy] -2-pyridinyl} -2,5-dioxo-1-phenyl- 1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt as an active ingredient, and which is characterized in that is administered in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination of the present invention has a high anti-tumor effect and is therefore useful in the treatment of solid cancers. |